Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly and Company to develop and commercialize treatments targeting cardiovascular and metabolic diseases. Olix will grant Eli ...

Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...

SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and ...

Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a phase 1 candidate for metabolic-associated steatohepatitis (MASH) and other ...

After signing the contract, OliX will grant exclusive licensing to Eli Lilly. Following the news of the contract signing, OliX Pharmaceuticals rose 29.93% the previous day, closing at the ceiling ...

This is Lilly’s second MASH deal this year, following its partnership with OliX Pharmaceuticals on the RNAi drug OLX75016. The OliX deal also included a drug with data supporting its use with a ...

The company entered into a global licensing deal with South Korea's OliX Pharmaceuticals that could be valued at up to $630 million. As per the agreement, Eli Lilly and Company (NYSE:LLY ...